DEC 04, 2019 9:00 AM PST

New Horizons for Protein Degradation: Immediate, Selective Protein Control Using the dTAG System

Speaker
  • Research Fellow, Dana-Farber Cancer Institute, Laboratory of Nathanael Gray
    Biography
      Behnam Nabet, Ph.D. is a Postdoctoral Research Fellow in the laboratory of Dr. Nathanael Gray at the Dana-Farber Cancer Institute. Dr. Nabet received his Ph.D. in Cancer Biology from Northwestern University and B.A. in Biology from the University of Pennsylvania. In his postdoctoral research, Dr. Nabet developed a generalizable technology platform known as the dTAG system to rapidly degrade any target protein of interest. The dTAG system pairs potent small molecule degraders and extensible tagging strategies to achieve selective degradation of divergent proteins. This technology facilitates biological exploration and drug target validation in cells and animal models. Dr. Nabet is currently applying the dTAG platform to investigate pancreatic cancer dependencies and has been sharing his technology with the global scientific community in an open-source manner. Dr. Nabet is supported by an American Cancer Society Postdoctoral Fellowship and is a recipient of the Claudia Adams Barr Program for Innovative Cancer Research award.

    Abstract
    DATE:  December 4, 2019
    TIME:   9:00am PST, 12:00pm EST
     
    Targeted protein degradation is a novel chemical modality centered on using pharmacological agents to immediately and selectively alter protein abundance. While there is a lack of research tools to perturb the majority of proteins in the proteome, hybrid chemical-genetic degradation systems have emerged as orthogonal means to modulate protein homeostasis. These degradation-based strategies are highly complementary to widely used genetic approaches, while offering improved target selectivity profiles and enabling functional studies with superior kinetic resolution. One novel strategy, the degradation tag (dTAG) system, uses heterobifunctional small molecule degraders to co-opt the cellular degradation machinery to rapidly and selectively dispose of tagged proteins. This webinar will summarize the dTAG technology platform and highlight case studies demonstrating utility for target-specific protein degradation. The dTAG system is a versatile tool for pre-clinical target validation and biological investigation in cellular and mouse models.
     
    Learning Objectives:
    • Demonstrate an understanding around the application of targeted protein degradation strategies
    • Discover how the dTAG system can be applied to selectively degrade proteins
    • Develop insights into how the dTAG system can be used for target validation and mechanistic studies
     
     
    Webinars will be available for unlimited on-demand viewing after live event.
     
    LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.

    Show Resources
    You May Also Like
    DEC 02, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    OCT 08, 2020 7:00 AM PDT
    C.E. CREDITS
    OCT 08, 2020 7:00 AM PDT
    DATE: October 8, 2020 TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop thinking about ho...
    AUG 25, 2020 8:00 AM PDT
    C.E. CREDITS
    AUG 25, 2020 8:00 AM PDT
    DATE: August 25, 2020 TIME: 8:00am PDT, 10:00am CDT, 11:00am EDT Recombinant lentivirus (LV) and adeno-associated virus (AAV) are critical components of cell and gene therapies, which show g...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    DEC 04, 2019 9:00 AM PST

    New Horizons for Protein Degradation: Immediate, Selective Protein Control Using the dTAG System


    Specialty

    Molecular Biology

    Cell Biology

    Cancer Research

    Immunology

    Biotechnology

    Cell Culture

    Biochemistry

    Genetics

    Molecular Diagnostics

    Gene Expression

    Biomarkers

    Cancer Therapeutics

    Cell Signaling / Transduction

    Dna

    Cancer Diagnostics

    Geography

    North America54%

    Europe25%

    Asia14%

    South America3%

    Oceania2%

    Africa2%

    Registration Source

    Website Visitors46%

    Email Promotions26%

    WAVE Newsletter Promotion4%

    Trending Newsletter Promotion2%

    Other22%

    Job Title

    Educator/Faculty17%

    Student15%

    Scientist14%

    Research Scientist14%

    Medical Laboratory Technician10%

    Executive8%

    Post Doc5%

    Clinical Laboratory Scientist5%

    Facility/Department Manager4%

    Chemist2%

    Medical Doctor/Specialist2%

    Biologist2%

    Lab Management2%

    Consultant1%

    Organization

    Academic Institution38%

    Biotech Company10%

    Clinical Laboratory8%

    Hospital8%

    Pharmaceutical Company7%

    Research Institute4%

    Medical School3%

    Government3%

    Life Science Company2%

    Contract Research Organization (Cro)2%

    Consultant2%

    Medical Center2%

    Diagnostic Company1%

    Government/public1%

    Other3%


    Show Resources
    Loading Comments...
    Show Resources
    Attendees
    • See more